Efficacité de l’infliximab versus adalimumab dans l’artérite de TAKAYASU
Savino Sciscia(Centre for Biomedical Network Research on Rare Diseases), Pavel Novikov(Sechenov University), Olivier Espitia(Centre National de la Recherche Scientifique), Lorenzo Dagna(Vita-Salute San Raffaele University), Carlo Salvarani(Sorbonne Université), Abid Awisat(Bnai Zion Medical Center), N. Schleinitz(Assistance Publique Hôpitaux de Marseille), Lucie Biard(Collaborative Group (United States)), José Hernández‐Rodríguez(Hospital Clínic de Barcelona), Xavier Puéchal(Université Paris Cité), Martin Michaud(Centre Hospitalier Universitaire de Toulouse), A. Mékinian(Sorbonne Université), Marc Lambert(Sorbonne Université), Sarah Meneses(Inserm)
Cited by 0
Related Papers
Proinflammatory Cytokines, Aging, and Age-Related Diseases
|Journal of the American Medical Directors Association|2013|1.1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
2018 update of the EULAR recommendations for the management of Behçet's syndrome
|Annals of the Rheumatic Diseases|2018|771
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
|Frontiers in Pharmacology|2019|616